National Institute for Health and Clinical Excellence (NICE)
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE recently (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
The guidelines aim to help healthcare professionals determine what care should be provided for people without COVID-19 infection or with confirmed or suspected COVID-19 infection safely and enable services to make the best use of NHS resources.
The guideline on CKD recommends that patients, including those who have symptoms of COVID-19, should be advised to continue taking their medicines (including ACE inhibitors, angiotensin receptor blockers, immunosuppressants and diuretics) as normal unless advised to stop by their healthcare professional.
For patients who are stable on treatment, the guideline recommends they should be assessed to see whether it is safe to reduce the frequency of routine kidney function tests, taking into account any comorbidities and whether their CKD is progressive.
It also says patients who are able to should be encouraged to self-monitor and self-manage (including blood pressure monitoring). Patients who do this should be given access to their medical data (including diagnosis, comorbidities, test results, treatments and correspondence) through information systems such as PatientView, as well as information about when they should seek help and who to contact.
The guideline also advises that patients should continue to be referred
for outpatient appointments if the clinical need is urgent. Patients should also be referred for ultrasound if the result might immediately change their management for example if they have accelerated progression of CKD, or symptoms of urinary tract obstruction.
The guideline on interstitial lung disease provides clinicians with advice on how to adjust care to reduce patients’ exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic.
It recommends that, for people newly referred to specialist services, wherever possible existing pulmonary function tests, blood tests and CT scan results should be used to guide diagnosis and treatment. If these results are not available but are needed to guide urgent care, patients should be referred for the relevant tests.
The guideline also highlights that, because bronchoscopy and pulmonary function tests have the potential to spread COVID-19, they should only be carried out if the patient urgently needs them and if the results will have a direct impact on their care.
When considering whether to start or continue treatment with an immunosuppressant, the guideline recommends that the risks and benefits should be discussed with the patient and involve all relevant members of the hospital specialist team. Factors such as whether the required monitoring and review are feasible, if it would be safer to delay starting the drug, and if there are any changes to the dose or route of administration that could make hospital attendance less likely, should all be considered.
Patients already taking antifibrotic drugs should be advised to continue their treatment because there is no evidence they increase the risk of getting COVID-19 or predispose patients to more severe disease.
NICE is collaborating internationally to make the guidelines available so that health systems around the world can see the approach the UK is taking.
The guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group, supported by the specialist societies and Royal Colleges.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends treatment for type of small-cell lung cancer28/05/2020 09:15:00
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
NICE chairman Sharmila Nebhrajani begins her new role27/05/2020 09:15:00
NICE is delighted to announce that Sharmila Nebhrajani, OBE, yesterday (26 May 2020) took up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE22/05/2020 15:10:00
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body
NICE draft guidance recommends new treatment option for people with early breast cancer07/05/2020 12:25:00
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer
New COVID-19 guideline on acute kidney injury07/05/2020 09:15:00
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).
NICE publishes latest wave of COVID-19 guidelines04/05/2020 13:33:00
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
NICE joins international collaboratives to respond to the COVID-19 pandemic01/05/2020 09:15:00
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
NICE publishes two new COVID-19 guidelines24/04/2020 11:15:00
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response14/04/2020 11:15:00
NICE recently (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19.